{"filings":[{"id":862476,"accession_number":"0001493152-26-027290","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2026-06-04T20:45:41+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Biomerica sells Diagnosis stake for $500k to CEO-affiliated buyers; note forgivable on transfer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Biomerica sells its 6% stake in Diagnosis S.A. (78,750 shares) to CEO-affiliated entities for $500,000.","CEO Zackary Irani directly acquires $300,000 of the shares; two LLCs buy $200,000 total.","Payments initially made via secured promissory note at 8% interest, due in 12 months; note forgiven upon share transfer.","Transfer requires Polish regulatory approvals expected within 30 days after closing.","Biomerica received $52,000 dividend from Diagnosis in 2026, disclosed to buyers prior to sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130558,"accession_number":"0001493152-25-027891","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomerica stockholders elect all 5 director nominees, approve share increase from 25M to 300M at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with majority votes: Irani, Barbieri, Bing Chin, Huff, Moatazedi.","Non-binding advisory vote on executive compensation passed (411,157 for, 87,344 against).","Ratification of Haskell & White LLP as independent auditor for FY ending May 31, 2026 approved (1,472,716 for).","Amendment to 2024 Stock Incentive Plan to increase shares by 200,000 approved (371,339 for).","Amendment to Certificate of Incorporation to increase authorized common stock from 25M to 300M approved (1,028,102 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130557,"accession_number":"0001493152-25-017363","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biomerica appoints former LabCorp Diagnostics CEO Gary Huff to board; director Emerson not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Huff appointed as independent director effective Oct 7, 2025; will serve on Audit, Comp, and Governance committees.","Huff receives annualized cash fee of $45,000 (paid quarterly); no equity compensation granted for board appointment.","Dr. Jane Emerson to step down after 18 years on board, not seeking re-election at Dec 12, 2025 annual meeting; board size to reduce to 5.","Huff brings 35+ years of lab industry experience, having served as CEO of LabCorp Diagnostics and Baylor Genetics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165654,"accession_number":"0001641172-25-013942","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biomerica appoints Eric Chin to board; Cathy Coste resigns effective June 4","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Cathy Coste resigned as director effective June 4, 2025; no disagreement with the company.","Eric Chin appointed as independent director and Audit Committee Chair, effective same date.","Chin is CFO of Akido Labs, helped raise $60M; will receive $41K annual cash and 10,000 restricted shares.","Chin also joins Nominating/Governance and Compensation Committees.","No family relationships or transactions requiring disclosure; board determined independent per Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":165653,"accession_number":"0001641172-25-004976","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Biomerica implements 1-for-8 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio of 1-for-8 reduces shares outstanding from ~20.4M to ~2.5M.","Effective 12:01 a.m. ET on April 21, 2025; split-adjusted trading begins that day.","New CUSIP 09061H406; no fractional shares issued (partial shares rounded up).","Purpose: increase bid price to meet Nasdaq minimum bid price requirement for continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199846,"accession_number":"0001493152-24-050432","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomerica shareholders approve reverse stock split authorization and 2024 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with overwhelming support; broker non-votes 5.5M.","Say-on-pay passed with 4.6M for vs 275K against; auditor Haskell & White ratified.","2024 Stock Incentive Plan approved (4.2M for, 730K against); 5.5M broker non-votes.","Reverse stock split authorization approved 9.8M for, 558K against; no broker non-votes.","Authorized share increase passed 9.6M for; adjournment proposal also approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199845,"accession_number":"0001493152-24-043867","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biomerica gets Nasdaq extension until May 5, 2025 to regain $1 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension on Nov 5, 2024; new compliance deadline is May 5, 2025.","Must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.","If not compliant by May 5, 2025, Nasdaq will issue delisting notice, subject to appeal.","Company will monitor bid price and consider options but no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235307,"accession_number":"0001493152-24-025656","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biomerica Chairman Jack Kenny resigns from board effective June 26, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jack Kenny resigned as board member and Chairman, effective June 26, 2024.","Resignation was not due to any disagreement with the company.","No replacement for Chairman or board seat has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235306,"accession_number":"0001493152-24-018697","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["1.01","3.01","9.01"],"status":"ready","headline":"Biomerica receives Nasdaq bid price deficiency notice; enters $5.5M at-market stock offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Biomerica on May 7, 2024 that bid price was below $1.00 for 32 consecutive business days, violating Listing Rule 5550(a)(2).","Company has 180 days (until Nov 4, 2024) to regain compliance; 10 consecutive days at $1.00+ required.","Entered At Market Issuance Sales Agreement with EF Hutton and R.F. Lafferty on May 10, 2024 to sell up to $5.5M of common stock.","Proceeds for general corporate purposes including sales/marketing, clinical studies, product development, acquisitions, and working capital.","Sales Agents receive 2.0% commission per share sold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270589,"accession_number":"0001493152-23-044431","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-12-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomerica reports voting results from 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected six director nominees: Zackary Irani (5,973,554 for), Allen Barbieri, Jane Emerson, Catherine Coste, David Moatazedi, Jack Kenny.","Advisory vote on named executive officer compensation ratified: 5,964,147 for, 94,156 against, 6,806 abstentions.","Ratified Haskell & White LLP as auditor for FY ending May 31, 2024: 10,546,099 for, 21,702 against, 6,381 abstentions.","Approved 2023 Stock Incentive Plan: 5,515,057 for, 87,185 against, 462,867 abstentions, 4,509,073 broker non-votes.","Approved adjournment of annual meeting if necessary: 5,906,540 for, 152,436 against, 6,133 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287519,"accession_number":"0001493152-23-033030","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-09-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biomerica submits final H. pylori dataset to FDA for 510(k) review of hp+detect test","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submitted final H. pylori data-set to FDA on Sep 15, 2023, as requested during FDA's 510(k) review.","FDA confirmed receipt of the data; Biomerica's hp+detect test detects H. pylori bacteria.","H. pylori infects approximately 35% of the U.S. population."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287518,"accession_number":"0001493152-23-030303","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-08-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Biomerica appoints former Meridian CEO Jack Kenny to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective August 25, 2023; Board expanded to add independent director.","Kenny will chair Nominating and Corporate Governance Committee and serve on Audit Committee.","Annual cash fee of $52,500 (paid quarterly); equity compensation to be determined later.","Kenny previously led Meridian Bioscience as CEO, overseeing its $1.53B all-cash sale.","Kenny to support launch of inFoods IBS test, which targets 40M+ U.S. IBS patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287517,"accession_number":"0001513162-23-000117","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Biomerica amends bylaws to change voting standard to limit broker non-vote effect","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved bylaw amendment on July 24, 2023, effective immediately.","Voting standard changed: from majority of stockholders present at meeting to majority present and entitled to vote on the subject matter.","Change aims to limit broker non-vote impact on non-routine proposals, given large retail shareholder base.","Other minor updates to modernize bylaws and align with Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":307715,"accession_number":"0001513162-23-000074","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biomerica discloses partnership with Gastro Health; no financial terms given","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["New relationship with Gastro Health, a group of over 390 physicians and 100+ care centers across seven states.","Gastro Health centers operate in AL, FL, MD, MA, OH, VA, and WA.","Investor presentation includes slides on the collaboration but omits deal value or revenue projections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326687,"accession_number":"0001513162-23-000034","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Biomerica closes $8M public offering of 3.33M shares at $2.40/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $8M gross, ~$7.4M net from 3,333,333 shares at $2.40/share via Craig-Hallum.","Net proceeds for clinical studies, sales expansion, R&D, acquisitions, and working capital.","Directors and officers agreed to 90-day lock-up on stock sales post-closing.","Offering closed March 7, 2023; underwriter discount 6%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326686,"accession_number":"0001513162-23-000023","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biomerica appoints Gary Lu as CFO effective March 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Lu, 42, previously Controller/VP Finance at Happy Money (Sep 2019-Feb 2023).","Lu receives $260,000 base salary and option for 75,000 shares vesting 25% annually over 4 years.","Steve Sloan steps down as interim CFO but remains advisor through Q3 FY2023 10-Q filing.","Lu is a CPA with a BA in Economics/Accounting from UCLA; began career at Ernst & Young."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326685,"accession_number":"0001513162-23-000015","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biomerica presents investor presentation; no specific material facts from provided exhibit text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["On February 6, 2023, Biomerica delivered an investor presentation to the investment community.","Exhibit 99.1 is attached but the actual slide content was not included in the filing text provided.","No financial results, guidance, or operational updates are discernible from the available filing information.","The filing is a routine Regulation FD disclosure; no new material events or transactions are reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344405,"accession_number":"0001513162-22-000153","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K/A","filed_at":"2022-12-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomerica corrects 8-K: 2022 Stock Incentive Plan not approved at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 5 (2022 Stock Incentive Plan) failed under correct majority-of-outstanding-shares standard; 2,395,243 for, 2,227,813 against, 2,475,235 broker non-votes.","Original 8-K incorrectly used majority-of-votes-cast standard; amended to reflect correct bylaw requirement.","All five director nominees elected; advisory say-on-pay and frequency (1 year) approved; Haskell & White LLP ratified as auditor.","7,126,662 shares present out of 13,474,338 outstanding; plan needed >3,563,331 affirmative votes based on shares entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344410,"accession_number":"0001513162-22-000148","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biomerica amends incentive plan to require stockholder vote for option repricing or buyouts","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously approved amendments removing ability to reprice or buy out options without stockholder approval.","Amendments delete Plan Sections 5.6 and 5.7, which previously allowed such actions without a vote.","Plan was originally approved by stockholders on Dec 7, 2022; amendments add further restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344409,"accession_number":"0001513162-22-000147","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Biomerica CFO Steve Sloan resigns; stays interim while search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Steve Sloan notified resignation on Dec 12, 2022 to pursue new career opportunity.","Sloan will serve as interim CFO while company conducts a search for a permanent replacement.","Vice Chairman Allen Barbieri will assist financial and accounting departments until new CFO is appointed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344408,"accession_number":"0001513162-22-000140","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomerica shareholders elect all five director nominees; approve 2022 Stock Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zackary Irani elected with 4,584,648 votes; all nominees received majority of votes cast.","Advisory say-on-pay passed with 4,570,514 votes for (44,365 against, 36,548 abstain).","Stockholders voted for every-one-year frequency for future say-on-pay votes (3,466,478 in favor).","Ratification of Haskell & White LLP as auditor for FY ending May 31, 2023 approved (7,047,314 for).","2022 Stock Incentive Plan approved with 2,395,243 votes for, 2,227,813 against, 28,371 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344407,"accession_number":"0001513162-22-000139","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mark Sirgo steps down; David Moatazedi elected to Biomerica board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Sirgo left the Board of Directors on December 7, 2022 at the annual shareholder meeting.","Sirgo was not nominated for re-election; his departure was previously announced in proxy materials.","Shareholders elected David Moatazedi to fill the seat vacated by Sirgo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344406,"accession_number":"0001513162-22-000131","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biomerica posts updated investor presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation posted on company website; no financial or operational details provided in the 8-K.","Presentation furnished as Exhibit 99.1; content not summarized in the filing text.","No earnings, guidance, or material events referenced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380047,"accession_number":"0001513162-22-000056","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-04-19T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Biomerica dismisses PKF San Diego as auditor, engages Haskell & White","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed PKF San Diego effective April 19, 2022.","No disagreements or reportable events in past two fiscal years or interim period.","Haskell & White LLP appointed as independent auditor for year ending May 31, 2022.","Change driven by company growth and desire for a larger audit firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398189,"accession_number":"0001513162-22-000014","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2022-02-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biomerica reports positive InFoods IBS endpoint trial results; multiple key endpoints show statistical significance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subject Global Assessment of Relief (SGA) endpoint achieved p=0.007 for all IBS subtypes at 8 weeks.","Global Improvement Scale (GIS) endpoint p=0.040 for all patient subtypes (baseline vs 8 weeks).","Abdominal Pain Intensity endpoint p=0.012 for IBS-Mixed & IBS-Constipation patients as a group.","Bloating endpoint p=0.022 for IBS-Mixed & IBS-Constipation patients as a group (baseline vs 8 weeks).","Company plans to meet with FDA to review results and finalize pivotal trial for FDA clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417212,"accession_number":"0001513162-21-000162","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Biomerica preliminary Q2 revenue $4.6M (+238% YoY); backlog $4M; InFoods trial data due Jan 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue approximately $4.6M for Q2 ended Nov 30, 2021, up 238% from $1.4M a year ago, driven by COVID test demand.","Operating loss expected between $0.9M and $1.3M; logistics constraints and higher shipping costs hurt margins.","Backlog of unfilled orders exceeds $4.0M entering Q3; cash balance over $7M, partly from prepayments.","InFoods IBS clinical trial data collection complete; topline results expected by end of January 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":5908687.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417211,"accession_number":"0001513162-21-000144","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2021-12-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biomerica shareholders elect all five director nominees and approve say-on-pay at 2021 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five nominees (Zackary Irani, Catherine Coste, Allen Barbieri, Jane Emerson, Mark Sirgo) elected with ~4.86M-4.87M votes for each.","Say-on-pay advisory vote passed with 4,805,845 for, 64,181 against, 34,334 abstain; broker non-votes 3,213,785.","Frequency of future advisory votes set at every one year (3,692,928 votes for one year, 1,106,395 for three years).","Ratification of PFK, LLP as independent auditor for FY ending May 31, 2022 approved with 8,085,541 for, 25,661 against.","Approximately 8.12M shares voted out of 12.51M outstanding; broker non-votes present on all proposals except auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417210,"accession_number":"0001513162-21-000141","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2021-12-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"SEC concludes investigations into Biomerica and CEO with no enforcement action","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC notified Biomerica on Dec 2, 2021 that subpoena investigations from July & Dec 2020 are closed with no enforcement action.","Investigations covered both the company and its CEO; full clearance granted.","Management expresses relief and ability to focus on business growth.","Removes a regulatory overhang that had been disclosed since mid-2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":434755,"accession_number":"0001513162-21-000116","cik":73290,"company_name":"BIOMERICA INC","ticker":"BMRA","form_type":"8-K","filed_at":"2021-09-30T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Biomerica restates FY2021 & earlier results due to stock-based compensation accounting errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-cash stock-based compensation was understated; expensed on vesting dates instead of ratably over vesting period, with incorrect forfeiture estimates.","FY2021 net loss to increase by $0.9M-$1.1M; FY2020 net loss to increase by $0.3M-$0.39M; pre-FY2020 cumulative adjustment of $0.75M-$0.95M to accumulated deficit.","No impact on cash, revenues, or operations; no misconduct found; Audit Committee retained third-party advisory firm to assist.","Company will file amended 10-K for FY2021 and restate quarterly reports for Q1-Q3 FY2021; prior financials should no longer be relied upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7586610.961538461,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}